Pfizer Vaccine to Apply for “95% Effectiveness” Emergency Use Permit November 19 at 6:20 AM
Pfizer, the American pharmaceutical giant, today announced its final analysis of the effectiveness of the new coronavirus vaccine under development, which is 95 percent effective, and will apply to the FDA’s U.S. Food and Drug Administration for emergency use in the next few days.
Pfizer, the American pharmaceutical giant, today announced the final analysis of the effectiveness of vaccines in clinical trials for vaccines it is developing with German company Biontec.
As a result, of the more than 40,000 people involved in clinical trials, 170 were infected with the new coronavirus.
Of these, eight were vaccinated, whereas 162 were vaccinated against a placebo called a placebo, and the effectiveness of the vaccine was 95%.
There were 10 cases of severe disease, but one in the vaccinated group and nine in the placebo group.
Pfizer said no serious safety concerns were reported to vaccinated people, but after the second vaccination, 3.8% of people felt lazy and 2% had headaches.
Pfizer then says it will apply to the FDA’s U.S. Food and Drug Administration in the next few days for “emergency use” permits to allow limited use of the drug under development before formal approval.
If the application is made, the FDA will consult an expert committee to determine whether to issue a permit, but FDA executives have told local media that the review will take “several weeks.”
On Pfizer’s vaccine, the Japanese government has agreed on a basic agreement to receive a supply of 60 million people by the end of June next year.